Evidence map›Paper›PMID 38835497›Full record

ArticleOpen forum infectious diseases2024

The Incidence of Skin and Soft Tissue Infections in the United States and Associated Healthcare Utilization Between 2010 and 2020.

Venanzio Vella, Dominique Derreumaux, Emmanuel Aris, Michele Pellegrini, Mario Contorni, Michael Scherbakov, Fabio Bagnoli

Abstract read
In one paragraph

Article in Open forum infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Real-Time Detection of Burn Wound Infection via a Turn-On NIR-II Fluorescent Probe.Chemistry (Weinheim an der Bergstrasse, Germany) · 2026
    Article
  8. Review
  9. Constitutional symptoms and response to Penicillin G in erysipelas and cellulitis - a monocentric, retrospective, explorative study.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2026
    Article
  10. Hospital Cost Components and Predictors inTropical medicine and infectious disease · 2026
    Article
  11. Microbiology spectrum · 2026
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Venanzio VellaVaccine Epidemiology-Bacterial, GSK, Siena, Italy.ORCID https://orcid.org/0000-0002-3213-6258
Dominique DerreumauxReal World Analytics, GSK, Wavre, Belgium.
Emmanuel ArisReal World Analytics, GSK, Wavre, Belgium.ORCID https://orcid.org/0000-0001-8640-1742
Michele PellegriniVaccines Clinical Sciences, GSK, Siena, Italy.ORCID https://orcid.org/0000-0001-8505-9260
Mario ContorniEarly Bacterial Vaccine Program, GSK, Siena, Italy.
Michael ScherbakovGlobal Medical Affairs, GSK, Wavre, Belgium.ORCID https://orcid.org/0000-0002-9189-4729
Fabio BagnoliInfectious Diseases Research Unit, GSK, Siena, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The number of patients with skin and soft tissue infections (SSTIs) in the United States appeared to be increasing well into the 21st century. However, no recent data have confirmed this trend. Methods: This retrospective, observational cohort study used claims data over 11 years (2010-2020) from Optum's de-identified Clinformatics Data Mart Database. SSTI episodes, complications, and comorbidities were identified using Results: During the study period, 5.4 million patients experienced 9.1 million SSTI episodes, with an incidence of 77.5 (95% confidence interval, 77.4-77.5) per 1000 person-years of observation (PYO). Annual incidence did not change significantly over time. Overall incidence (per 1000 PYO) of SSTI episodes in patients without comorbidities was 32.1 (highest incidence was for previous SSTI [113.5]) versus much higher rates if comorbidities were present. Incidence rates (per 1000 PYO) of chronic ulcers increased over time from 11.3 to 18.2 ( Conclusions: The epidemiology of SSTI in the United States is changing and the disease burden is increasing despite stabilization in overall incidence. These data can inform identification of priority populations who could benefit from targeted interventions.

Indexed as

chronic ulcerepidemiologyhealthcare costsincidenceskin and soft tissue infections

Identifiers

PMID38835497
PMCPMC11146672

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.